MX2022006046A - Compuesto cannabinoide tipo cannabidiol. - Google Patents
Compuesto cannabinoide tipo cannabidiol.Info
- Publication number
- MX2022006046A MX2022006046A MX2022006046A MX2022006046A MX2022006046A MX 2022006046 A MX2022006046 A MX 2022006046A MX 2022006046 A MX2022006046 A MX 2022006046A MX 2022006046 A MX2022006046 A MX 2022006046A MX 2022006046 A MX2022006046 A MX 2022006046A
- Authority
- MX
- Mexico
- Prior art keywords
- cannabidiol
- cbdv
- cannabinoid compound
- type cannabinoid
- type
- Prior art date
Links
- 229930003827 cannabinoid Natural products 0.000 title abstract 4
- 239000003557 cannabinoid Substances 0.000 title abstract 4
- 150000001875 compounds Chemical class 0.000 title abstract 2
- REOZWEGFPHTFEI-JKSUJKDBSA-N Cannabidivarin Chemical compound OC1=CC(CCC)=CC(O)=C1[C@H]1[C@H](C(C)=C)CCC(C)=C1 REOZWEGFPHTFEI-JKSUJKDBSA-N 0.000 abstract 4
- REOZWEGFPHTFEI-UHFFFAOYSA-N cannabidivarine Natural products OC1=CC(CCC)=CC(O)=C1C1C(C(C)=C)CCC(C)=C1 REOZWEGFPHTFEI-UHFFFAOYSA-N 0.000 abstract 4
- QHMBSVQNZZTUGM-UHFFFAOYSA-N Trans-Cannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1C1C(C(C)=C)CCC(C)=C1 QHMBSVQNZZTUGM-UHFFFAOYSA-N 0.000 abstract 2
- QHMBSVQNZZTUGM-ZWKOTPCHSA-N cannabidiol Chemical compound OC1=CC(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)=C)CCC(C)=C1 QHMBSVQNZZTUGM-ZWKOTPCHSA-N 0.000 abstract 2
- 229950011318 cannabidiol Drugs 0.000 abstract 2
- ZTGXAWYVTLUPDT-UHFFFAOYSA-N cannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1C1C(C(C)=C)CC=C(C)C1 ZTGXAWYVTLUPDT-UHFFFAOYSA-N 0.000 abstract 2
- PCXRACLQFPRCBB-ZWKOTPCHSA-N dihydrocannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)C)CCC(C)=C1 PCXRACLQFPRCBB-ZWKOTPCHSA-N 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C37/00—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C37/00—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom of a six-membered aromatic ring
- C07C37/001—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom of a six-membered aromatic ring by modification in a side chain
- C07C37/002—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom of a six-membered aromatic ring by modification in a side chain by transformation of a functional group, e.g. oxo, carboxyl
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C37/00—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom of a six-membered aromatic ring
- C07C37/01—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom of a six-membered aromatic ring by replacing functional groups bound to a six-membered aromatic ring by hydroxy groups, e.g. by hydrolysis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C37/00—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom of a six-membered aromatic ring
- C07C37/68—Purification; separation; Use of additives, e.g. for stabilisation
- C07C37/70—Purification; separation; Use of additives, e.g. for stabilisation by physical treatment
- C07C37/82—Purification; separation; Use of additives, e.g. for stabilisation by physical treatment by solid-liquid treatment; by chemisorption
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C39/00—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring
- C07C39/02—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring monocyclic with no unsaturation outside the aromatic ring
- C07C39/08—Dihydroxy benzenes; Alkylated derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C39/00—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring
- C07C39/23—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring polycyclic, containing six-membered aromatic rings and other rings, with unsaturation outside the aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/16—Systems containing only non-condensed rings with a six-membered ring the ring being unsaturated
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
La presente invención se refiere a un compuesto cannabinoide de tipo cannabidiol (CBD) para uso como medicamento. El cannabinoide de tipo CBD, 6-hidroxi cannabidivarina (6-OH CBDV), es un metabolito de cannabidivarina (CBDV). El cannabinoide se puede producir por medios sintéticos y en la presente invención se describe un método para la producción de 6-OH CBDV. Además, aquí se presentan datos que demuestran la eficacia de 6-OH CBDV en un modelo de enfermedad.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1916977.0A GB201916977D0 (en) | 2019-11-21 | 2019-11-21 | Cannibidol-type cannabinoid compound |
| PCT/GB2020/052944 WO2021099783A1 (en) | 2019-11-21 | 2020-11-18 | Cannabidiol-type cannabinoid compound |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022006046A true MX2022006046A (es) | 2022-06-24 |
Family
ID=69137226
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022006046A MX2022006046A (es) | 2019-11-21 | 2020-11-18 | Compuesto cannabinoide tipo cannabidiol. |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US11590087B2 (es) |
| EP (1) | EP4061345A1 (es) |
| JP (1) | JP2023503309A (es) |
| KR (1) | KR20220103998A (es) |
| CN (1) | CN114746086A (es) |
| AU (1) | AU2020388278A1 (es) |
| BR (1) | BR112022009580A2 (es) |
| CA (1) | CA3158192A1 (es) |
| GB (2) | GB201916977D0 (es) |
| IL (1) | IL293035A (es) |
| MX (1) | MX2022006046A (es) |
| TW (1) | TW202132250A (es) |
| WO (1) | WO2021099783A1 (es) |
| ZA (1) | ZA202206386B (es) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2530001B (en) | 2014-06-17 | 2019-01-16 | Gw Pharma Ltd | Use of cannabidiol in the reduction of convulsive seizure frequency in treatment-resistant epilepsy |
| GB2531282A (en) | 2014-10-14 | 2016-04-20 | Gw Pharma Ltd | Use of cannabinoids in the treatment of epilepsy |
| GB2539472A (en) | 2015-06-17 | 2016-12-21 | Gw Res Ltd | Use of cannabinoids in the treatment of epilepsy |
| GB201806953D0 (en) | 2018-04-27 | 2018-06-13 | Gw Res Ltd | Cannabidiol Preparations |
| AU2022275207A1 (en) * | 2021-05-12 | 2023-11-30 | GW Research Limited | Rescorcinols, methods for their manufacture, and uses thereof |
| WO2022238701A1 (en) * | 2021-05-12 | 2022-11-17 | GW Research Limited | Resorcinol derivative as a pharmaceutically active compound and method of preparation thereof |
| GB202206506D0 (en) * | 2022-05-04 | 2022-06-15 | Gw Res Ltd | Crystaline forms of a cannabidiol-like cannabinoid |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2002512188A (ja) | 1998-04-21 | 2002-04-23 | ザ ガバメント オブ ザ ユナイテッド ステイツ オブ アメリカ， アズ レプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ | 抗酸化剤及び神経保護剤としてのカンナビノイド類 |
| US10538373B2 (en) | 2002-08-14 | 2020-01-21 | Gw Pharma Limited | Pharmaceutical formulation |
| TWI583374B (zh) * | 2010-03-30 | 2017-05-21 | Ｇｗ伐瑪有限公司 | 使用植物大麻素次大麻二酚（ｃｂｄｖ）來治療癲癇之用途 |
| GB2495118B (en) * | 2011-09-29 | 2016-05-18 | Otsuka Pharma Co Ltd | A pharmaceutical composition comprising the phytocannabinoids cannabidivarin (CBDV) and cannabidiol (CBD) |
| US10441617B2 (en) | 2013-03-15 | 2019-10-15 | Biotech Institute, Llc | Breeding, production, processing and use of medical cannabis |
| GB2530001B (en) | 2014-06-17 | 2019-01-16 | Gw Pharma Ltd | Use of cannabidiol in the reduction of convulsive seizure frequency in treatment-resistant epilepsy |
| GB2527599A (en) * | 2014-06-27 | 2015-12-30 | Gw Pharma Ltd | Use of 7-OH-Cannabidiol (7-OH-CBD) and/or 7-OH-Cannabidivarin (7-OH-CBDV) in the treatment of epilepsy |
| GB2531281A (en) | 2014-10-14 | 2016-04-20 | Gw Pharma Ltd | Use of cannabidiol in the treatment of intractable epilepsy |
| GB2531280A (en) | 2014-10-14 | 2016-04-20 | Gw Pharma Ltd | Use of cannabidiol in the treatment of intractable epilepsy |
| GB2531282A (en) | 2014-10-14 | 2016-04-20 | Gw Pharma Ltd | Use of cannabinoids in the treatment of epilepsy |
| GB2531278A (en) | 2014-10-14 | 2016-04-20 | Gw Pharma Ltd | Use of cannabidiol in the treatment of intractable epilepsy |
| GB2539472A (en) | 2015-06-17 | 2016-12-21 | Gw Res Ltd | Use of cannabinoids in the treatment of epilepsy |
| GB2541191A (en) | 2015-08-10 | 2017-02-15 | Gw Pharma Ltd | Use of cannabinoids in the treatment of epilepsy |
| GB2548873B (en) | 2016-03-31 | 2020-12-02 | Gw Res Ltd | Use of Cannabidiol in the Treatment of SturgeWeber Syndrome |
| GB2551985B (en) | 2016-07-01 | 2019-01-30 | Gw Res Ltd | Novel formulation |
| GB2551987A (en) | 2016-07-01 | 2018-01-10 | Gw Res Ltd | Oral cannabinoid formulations |
| GB2551986A (en) | 2016-07-01 | 2018-01-10 | Gw Res Ltd | Parenteral formulations |
| GB2553139A (en) | 2016-08-25 | 2018-02-28 | Gw Res Ltd | Use of cannabinoids in the treatment of multiple myeloma |
| GB2557921A (en) | 2016-12-16 | 2018-07-04 | Gw Res Ltd | Use of cannabinoids in the treatment of angelman syndrome |
| GB2559774B (en) | 2017-02-17 | 2021-09-29 | Gw Res Ltd | Oral cannabinoid formulations |
| CN109106699A (zh) * | 2017-06-23 | 2019-01-01 | 汉义生物科技（北京）有限公司 | 一种用于治疗癫痫的药物组合物、其制备方法及用途 |
| GB2564383B (en) | 2017-06-23 | 2021-04-21 | Gw Res Ltd | Use of cannabidiol in the treatment of tumours assoicated with Tuberous Sclerosis Complex |
| GB201715919D0 (en) | 2017-09-29 | 2017-11-15 | Gw Res Ltd | use of cannabinoids in the treatment of epilepsy |
| GB2568471B (en) | 2017-11-15 | 2022-04-13 | Gw Res Ltd | Use of cannabinoids in the treatment of epilepsy |
| GB2568929A (en) | 2017-12-01 | 2019-06-05 | Gw Res Ltd | Use of cannabinoids in the treatment of epilepsy |
| GB2569961B (en) | 2018-01-03 | 2021-12-22 | Gw Res Ltd | Pharmaceutical |
| GB2572125B (en) | 2018-01-03 | 2021-01-13 | Gw Res Ltd | Pharmaceutical |
| GB2572126B (en) | 2018-01-03 | 2021-01-13 | Gw Res Ltd | Pharmaceutical |
| GB2572737A (en) | 2018-01-24 | 2019-10-16 | Gw Res Ltd | Use of cannabinoids in the treatment of epilepsy |
| GB201806953D0 (en) * | 2018-04-27 | 2018-06-13 | Gw Res Ltd | Cannabidiol Preparations |
| GB2581517A (en) | 2019-02-22 | 2020-08-26 | Gw Res Ltd | Use of cannabinoids in the treatment of epilepsy |
| GB2584140A (en) | 2019-05-23 | 2020-11-25 | Gw Res Ltd | Use of cannabidiol in the treatment of epileptic spasms |
| GB2584341B (en) | 2019-05-31 | 2023-03-01 | Gw Res Ltd | Cannabinoid formulations |
| GB2586026A (en) | 2019-07-29 | 2021-02-03 | Gw Res Ltd | Use of cannabidol in the treatment of Dravet syndrome |
| GB202002754D0 (en) | 2020-02-27 | 2020-04-15 | Gw Res Ltd | Methods of treating tuberous sclerosis complex with cannabidiol and everolimus |
| US11160757B1 (en) | 2020-10-12 | 2021-11-02 | GW Research Limited | pH dependent release coated microparticle cannabinoid formulations |
-
2019
- 2019-11-21 GB GBGB1916977.0A patent/GB201916977D0/en not_active Ceased
-
2020
- 2020-11-18 KR KR1020227020695A patent/KR20220103998A/ko unknown
- 2020-11-18 MX MX2022006046A patent/MX2022006046A/es unknown
- 2020-11-18 AU AU2020388278A patent/AU2020388278A1/en active Pending
- 2020-11-18 BR BR112022009580A patent/BR112022009580A2/pt unknown
- 2020-11-18 IL IL293035A patent/IL293035A/en unknown
- 2020-11-18 GB GB2018139.2A patent/GB2590187B/en active Active
- 2020-11-18 JP JP2022529679A patent/JP2023503309A/ja active Pending
- 2020-11-18 CN CN202080080992.7A patent/CN114746086A/zh active Pending
- 2020-11-18 EP EP20815903.8A patent/EP4061345A1/en active Pending
- 2020-11-18 WO PCT/GB2020/052944 patent/WO2021099783A1/en active Application Filing
- 2020-11-18 CA CA3158192A patent/CA3158192A1/en active Pending
- 2020-11-20 TW TW109140702A patent/TW202132250A/zh unknown
-
2022
- 2022-05-13 US US17/743,653 patent/US11590087B2/en active Active
- 2022-06-08 ZA ZA2022/06386A patent/ZA202206386B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| TW202132250A (zh) | 2021-09-01 |
| GB202018139D0 (en) | 2020-12-30 |
| JP2023503309A (ja) | 2023-01-27 |
| GB2590187A9 (en) | 2023-03-15 |
| CA3158192A1 (en) | 2021-05-27 |
| EP4061345A1 (en) | 2022-09-28 |
| WO2021099783A1 (en) | 2021-05-27 |
| ZA202206386B (en) | 2023-12-20 |
| AU2020388278A1 (en) | 2022-06-16 |
| BR112022009580A2 (pt) | 2022-08-02 |
| US20220265573A1 (en) | 2022-08-25 |
| CN114746086A (zh) | 2022-07-12 |
| US11590087B2 (en) | 2023-02-28 |
| IL293035A (en) | 2022-07-01 |
| GB201916977D0 (en) | 2020-01-08 |
| GB2590187B (en) | 2024-07-31 |
| KR20220103998A (ko) | 2022-07-25 |
| GB2590187A (en) | 2021-06-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA202206386B (en) | Cannabidiol-type cannabinoid compound | |
| MX2021005919A (es) | Compuesto cannabinoide del tipo de cannabidiol. | |
| MX2022005995A (es) | Compuesto cannabinoide tipo cannabidiol. | |
| FI3743053T3 (fi) | Kannabinoidien käyttö epilepsian hoidossa | |
| PH12018500093A1 (en) | Process for the production of cannabidiol and delta-9-tetrahydrocannabinol | |
| NZ602925A (en) | Use of the phytocannabinoid cannabidivarin (cbdv) in the treatment of epilepsy | |
| TN2013000347A1 (en) | Production method of optically active dihydrobenzofuran derivative | |
| EA201391733A1 (ru) | Каннабиноиды, применяемые для лечения невропатической боли | |
| MX2009003382A (es) | Derivados de sulfonamidas sustituidos. | |
| BR112014007257A2 (pt) | composto, medicamento, métodos para inibir um colesterol 24-hidrolase em um mamífero e para a profilaxia ou tratamento de doença neurodegenerativa em um mamífero, e, uso do composto ou sal | |
| BR112014005018A8 (pt) | composição aquosa de ligante, ligante, método de produção de uma composição aquosa de ligante e método de fabricação de um produto selecionado de um grupo | |
| BR122019021714B8 (pt) | preparação compreendendo vitamina b12 e butanol e butafosfano, e seu uso | |
| MX2021005479A (es) | Plantas de cannabis con un perfil cannabinoides enriquecido para cannabidiol y ¿-9-tetrahidrocannabinol. | |
| MX2022005931A (es) | Compuesto cannabinoide tipo cannabidiol. | |
| CR20120082A (es) | Conservantes de derivados de quitina | |
| GB201319839D0 (en) | Synthesis and use of glycoside derivatives of propofol | |
| MX2022005933A (es) | Compuesto cannabinoide tipo cannabidiol. | |
| MX364633B (es) | Uso de cannabinoides en el tratamiento de enfermedades degenerativas del músculo esquelético. | |
| ECSP13012471A (es) | Método de producción de un compuesto intermediario para sintetizar un medicamento | |
| MX347630B (es) | 1-vinilciclohex-3-en carbaldehido y 4-vinilciclohex-1-en carbaldehido para el uso en composiciones saborizantes y para el cuidado oral. | |
| EA201270176A1 (ru) | Производные тазаротена | |
| MX2022004935A (es) | (+)- trans tetrahidrocannabinol ((+)-trans-thc) para uso como medicamento. | |
| MX2022004767A (es) | (+)-cis tetrahidrocannabinol ((+)-cis-thc) para uso como medicamento. | |
| MX2022004888A (es) | (-)-cis tetrahidrocannabinol ((-)-cis-thc) para uso como medicamento. | |
| WO2014111903A3 (en) | A process for the preparation of 6-fluoro-3,4-dihydro-2h-chromene- 2-carbaldehyde |